

**EXPORT LICENSE**

NRC FORM 250



**United States of America**  
 Nuclear Regulatory Commission  
 Washington, D.C. 20555

**NRC LICENSE NO.:** XMAT448/02

Page 1 of 11

**NRC DOCKET NO.:** 11006349

**LICENSE EXPIRES:** December 31, 2025

Pursuant to the Atomic Energy Act of 1954, as amended, and the Energy Reorganization Act of 1974 and the regulations of the Nuclear Regulatory Commission (NRC) issued pursuant thereto, and in reliance on the statements and representations herefore made by the licensee, a license is hereby issued to the licensee authorizing the export of the materials and/or production or utilization facilities listed below, subject to the terms and conditions herein.

|   |  |
|---|--|
| <p align="center"><b>LICENSEE</b></p> <p>Cambridge Isotope Laboratories, Inc.<br/>                 50 Frontage Road<br/>                 Andover, MA 01810</p> <p>Attn: Rebecca Dabkowski</p> | <p align="center"><b>ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES)</b></p> <p align="center">See following page(s)</p> |
| <p align="center"><b>INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES)</b></p> <p align="center">See following page(s)</p>  | <p align="center"><b>OTHER U.S. PARTY(IES) TO EXPORT</b></p> <p align="center">See following page(s)</p>               |

**APPLICANT'S REFERENCE:** XMAT448

**ULTIMATE DESTINATION:** India

|                             |   |
|-----------------------------|---|
| <p><b>QUANTITY(IES)</b></p> | <p align="center"><b>DESCRIPTION OF MATERIAL(S) OR FACILITY(IES)</b></p> <p>This license is amended to update the list of ultimate foreign consignees by adding 3 additional parties.</p> <p>The license is authorized to export a cumulative total of 10,000 kilograms of deuterium, in the form of deuterium oxide, deuterium gas, and other compounds. The cumulative total starts from the issuance of the original export license XMAT448.</p> |
|-----------------------------|---|

Neither this license nor any right under this license shall be assigned or otherwise transferred in violation of the provisions of the Atomic Energy Act of 1954, as amended, and the Energy Reorganization Act of 1974.

This license is subject to the right of recapture or control by Section 108 of the Atomic Energy Act of 1954, as amended, and to all the other provisions of said Acts, now or hereafter in effect and to all valid rules and regulations of the NRC.

**THIS LICENSE IS INVALID UNLESS SIGNED BELOW  
 BY AUTHORIZED NRC REPRESENTATIVE**

**SIGNATURE:** Peter J. Habighorst  
Digitally signed by Peter J. Habighorst  
 Date: 2020.12.31 07:17:32 -05'00'

**NAME AND TITLE:** Peter J. Habighorst, Acting Deputy Director  
 Office of International Programs

**DATE OF ISSUANCE:** December 31, 2020

**ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):**

1. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

2. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

3. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

4. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

5. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

6. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

7. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

8. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

**ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):**

9. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
10. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
11. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
12. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
13. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
14. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
15. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
16. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

**ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):**

17. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

18. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

19. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

20. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

21. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

22. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

23. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

24. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

**ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):**

25. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

26. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

27. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

28. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

29. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

30. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

31. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

32. [REDACTED]  
India  
(non-nuclear end use in active pharmaceutical ingredient (API) production)

**ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):**

33. [REDACTED]  
India  
(non-nuclear end use in active pharmaceutical ingredient (API) production)
34. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
35. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
36. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
37. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
38. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
39. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
40. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

**ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):**

41. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

42. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

43. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

44. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

45. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

46. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

47. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

48. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

**ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):**

49. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

50. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

51. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

52. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

53. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

54. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

55. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

56. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)



**ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):**

57. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

58. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

59. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

60. [REDACTED]  
India  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

**INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):**

1. [REDACTED]  
India  
(for distribution to ultimate consignees)

2. [REDACTED]  
India  
(for distribution to ultimate consignees)

3. [REDACTED]  
India  
(for distribution to ultimate consignees)

**INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):**

4. [REDACTED]  
India  
(for distribution to ultimate consignees)

5. [REDACTED]  
France  
(for distribution to ultimate consignees)

6. [REDACTED]  
India  
(for distribution to ultimate consignees)

7. [REDACTED]  
India  
(for distribution to ultimate consignees)

8. [REDACTED]  
India  
(for distribution to ultimate consignees)

9. [REDACTED]  
India  
(for distribution to ultimate consignees)

10. [REDACTED]  
India  
(for distribution to ultimate consignees)

**OTHER U.S. PARTY(IES) TO EXPORT:**

1. Cambridge Isotope Laboratories, Inc.  
50 Frontage Road  
Andover, MA 01810  
(supplier/distributors)
  
2. Cambridge Isotope Laboratories, Inc.  
6 Highwood Drive  
Tewksbury, MA 01876  
  
(supplier)
  
3. Cambridge Isotope Separations  
1689 Burnett Drive  
Xenia, OH 45385  
  
(supplier)